glp 1 therapies How to use GLP-1 receptor agonist therapy safely and effectively Discovery of GLP-1–Based Drugs for

AMs release fibrosis-associated cytokines such as TGF-1 and osteopontin (OPN), increase lysosomal membrane permeability, and promote the release of damage-associated molecular patterns (DAMPs), activating TLRs/NF-B, MAPKs, and other inflammatory signaling pathways (58, 109) (see Figure 4b)

AE leading to drug discontinuation were observed in 16% of participants with the 12 mg dose, but the overall incidence of SAE was low (up to 6-8%)

Tc dng ph t gp i vi nhng trng hp him gp, ngi dng c th b bun nn, tiu chy hoc chng mt

Image 1

5 Lower doses: Eight in ten real-world patients were on maintenance doses below 1.7 mg of semaglutide or 10 mg of tirzepatide